07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Igen, Boehringer Mannheim GmbH deal

IGEN received a $6 million advance payment on 1997 royalties from partner Boehringer Mannheim. The payments arise from sales of the pharma company's Elecsys series of immunodiagnostics based on IGEN's Origen technology. Origen provides uniform...
07:00 , Sep 25, 2008 |  BC Innovations  |  Tools & Techniques

Synthetic Dual-action Vaccines

U.S. and Canadian researchers have developed a technique to produce fully synthetic vaccines and have mouse data showing the prevention of candidiasis, a range of oral, vaginal and systemic yeast infections. 1 Although a candidiasis...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

BioVeris, Roche deal

ROG completed its acquisition of BIOV for $21.50 per share in cash, or about $600 million (see BioCentury, April 9). BioVeris Corp. (BIOV), Gaithersburg, Md.   Roche (SWX:ROG), Basel, Switzerland   Business: Diagnostic  ...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Company News

BioVeris, Roche deal

ROG said it will acquire BIOV for $21.50 per share in cash, or about $600 million. The deal price is a 58% premium to BIOV's close of $13.60 on April 3, the day before the...
07:00 , Apr 9, 2007 |  BioCentury  |  Finance

Ebb & Flow

Biotech venture investing hit record levels in the first quarter, totaling nearly $2 billion. That exceeds the previous high of more than $1.7 billion in the fourth quarter of 2000. VCs cited two reasons for...
00:40 , Apr 5, 2007 |  BC Extra  |  Top Story

Roche to acquire BioVeris

Roche (SWX:ROG) said it will acquire diagnostic company BIOV for $21.50 per share in cash, or about $600 million. The deal price is a 58% premium to BIOV's close of $13.60 on Tuesday. ROG said...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

BioVeris sales and marketing update

BIOV launched two products to detect the inflammatory cytokines IL-2 and TNF-alpha to measure potential immune responses to protein-based therapeutics. The company also launched a panel of six antibodies labeled with BIOV's detection label BV-TAG...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

BioVeris, Baxter deal

BIOV received exclusive worldwide rights to develop BAX’s Neisseria meningitidis group Y and Haemophilus influenza type b (Hib) vaccines as components in new combination vaccines to prevent meningitis, sepsis and pneumonia. The BAX vaccines are...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

BioVeris, Roche deal

BIOV received $2.8 million in royalties from ROG's Roche Diagnostics subsidiary for 2004 sales outside of ROG's licensed fields. Under a February 2004 deal, ROG has a worldwide, non-exclusive, royalty-free license to commercialize BIOV's electrochemiluminescense...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Company News

BioVeris, Baxter deal

BIOV received non-exclusive worldwide rights to develop BAX's Neisseria meningitidis group C vaccine as a component in new combination vaccines to prevent meningitis and sepsis. The BAX vaccine is in preclinical development. BAX received an...